Generic

Rabeprazole Sodium

Indications

Rabeprazole Gastro-resistant pills are used to treat the following conditions: Active duodenal ulcers

Gastric ulcer that is active and benign

Gastroesophageal reflux disease (GERD) that is symptomatic, erosive, or ulcerative (GERD).

Gastro-esophageal Reflux Disease (GERD) is a disease that affects the esophagus and Long-term planning (GERD Maintenance)

Symptomatic treatment for gastroesophageal reflux disease (GERD) ranging from mild to severe (symptomatic GERD)

Syndrome of Zollinger-Ellison

Helicobacter pylori eradication in patients with peptic ulcer disease in combination with appropriate antimicrobial treatment regimens.

Pharmacology

Rabeprazole inhibits the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell, which decreases gastric acid secretion. Rabeprazole has been classified as a gastric proton-pump inhibitor since this enzyme is thought to be the acid (proton) pump within the parietal cell.

Dosage & Administration

Active Duodenal Ulcer and Active Benign Gastric Ulcer: The recommended oral dose for both bioactive duodenal ulcer and active benign gastric ulcer is 20 mg to be taken once daily in the morning. Most patients with active duodenal ulcer heal within four weeks. However, a few patients may require an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcer heal within six weeks. However, again a few patients may require an additional six weeks of therapy to achieve healing.

Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20 mg to be taken once daily for four to eight weeks.

Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response.

Symptomatic treatment of moderate to very severe Gastro-Esophageal Reflux Disease (symptomatic GERD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10 mg once daily when needed.

Zollinger-Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated.

Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended. Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1g twice daily.

Interaction

Gastric acid secretion is profoundly and long-lastingly inhibited by respite. It’s possible that you’ll come into contact with a substance whose absorption is pH-dependent. When rabeprazole sodium is used with ketoconazole or itraconazole, antifungal plasma levels may be significantly reduced. When ketoconazole or itraconazole are used together with Respite, individual patients may need to be watched to see if a dosage adjustment is necessary. There was no interaction with liquid antacids. Atazanavir’s absorption is pH-dependent. As a result, PPIs, such as rabeprazole, should not be taken with atazanavir.

Contraindications

Hypersensitivity to the active ingredient or any excipient. Rabeprazole is not recommended during pregnancy or nursing.

Side Effects

Rabeprazole is generally well tolerated in both short and long-term studies. Headache, diarrhoea, abdominal discomfort, vomiting, constipation, dry mouth, increased or decreased hunger, muscle soreness, sleepiness, and dizziness are all possible side effects of rabeprazole.

Pregnancy & Lactation

Pregnancy category ‘C’ according to the US Food and Drug Administration. Rabeprazole has been studied in animals, and there has been no evidence of reduced fertility or injury to the fetus as a result of its use. However, no suitable and well-controlled studies in pregnant women have been conducted. Because rabeprazole is likely to be excreted in human milk, a choice should be taken on whether to stop breastfeeding or stop taking the medication, taking into account the drug’s importance to the mother.

Precautions & Warnings

Symptomatic reaction to treatment with Rabeprazole does not block the nearness of gastric or oesophageal danger, in this manner the plausibility of danger ought to be avoided earlier to commencing treatment with Rabeprazole 20 mg Gastro-resistant Tablets. Patients on long-term treatment (especially those treated for more than a year) ought to be kept beneath standard surveillance. Proton pump inhibitors, particularly in case utilized in tall dosages and over long terms (>1 year), may humbly increment the hazard of hip, wrist and spine break, overwhelmingly within the elderly or in nearness of other perceived hazard components. Observational ponders recommend that proton pump inhibitors may increment the in general hazard of break by 10–40%. A few of this increment may be due to other hazard variables. Patients at hazard of osteoporosis ought to get care and they ought to have an satisfactory admissions of vitamin D and calcium. chance of cross-hypersensitivity responses with other proton pump inhibitor or substituted benzimidazoles cannot be excluded.

Patients ought to be cautioned that Rabeprazole gastro-resistant tablets ought to not be chewed or smashed, but ought to be gulped whole. There have been post showcasing reports of blood dyscrasias (thrombocytopenia and neutropenia). Within the lion’s share of cases where an elective aetiology cannot be distinguished, the occasions were uncomplicated and settled on suspension of rabeprazole. Hepatic protein anomalies have been seen in clinical trials and have too been reported since advertise authorisation. Within the lion’s share of cases where an elective aetiology cannot be distinguished, the occasions were uncomplicated and settled on cessation of rabeprazole.

Therapeutic Class

Inhibitor of the proton pump.

Storage Conditions

Keep the temperature below 30°C and away from light and moisture. Keep out of children’s reach.

Pharmaceutical Name

Navana Pharmaceuticals Ltd.